Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

Cleary, John D.; Garcia-Effron, Guillermo; Chapman, Stanley W.; Perlin, David S.

doi:10.1128/aac.01568-07

Cited by 119Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal and yeast genetics research

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

Open access

Cleary, John D., Garcia-Effron, Guillermo, Chapman, Stanley W., Perlin, David S.·2008·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.01568-07PMC PMC2415792

Open this paper in CoChat — free account

Abstract

We describe a case of recurring Candida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.01568-07

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Echinocandin resistance has been found in most clinically relevant Candida species.
“It has been found in most clinically relevant Candida species, but is most common in C. glabrata with rates exceeding 10% at selected institutions.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
Echinocandin resistance has emerged in Candida over recent years.
“Echinocandin resistance has emerged over the recent years.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
Most reports of acquired echinocandin resistance are case reports or case series, which collectively document the potential of resistance development in almost all species that are not intrinsically susceptible.
“Most are case reports or case series, which collectively document the potential of resistance development in almost all species that are not intrinsically susceptible (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
Acquired echinocandin resistance has been reported in single isolates belonging to most Candida species including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis.
“Moreover, reports on acquired echinocandin resistance, defined as resistance among species that are normally susceptible, have emerged and today acquired resistance has been reported in single isolates belonging to most Candida species including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
Clinically relevant acquired echinocandin resistance in Candida has never been detected in the absence of FKS hot spot mutations.
“So far, clinically relevant acquired echinocandin resistance in Candida has never been detected in absence of FKS hot spot mutations.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736 · see citing works
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · see citing works
Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434 · see citing works
Self-citation
Multiechinocandin- and Multiazole-ResistantCandida parapsilosisIsolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis
Moudgal, V. V., Little, T., Boikov, D. A., & Vázquez, J. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.767-769.2005 · Cited by 241 · see citing works
Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient
Krogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/500939 · Cited by 201 · see citing works
In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.760-763.2006 · Cited by 195 · see citing works
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis
Laverdière, M., LALONDE, R. G., Baril, J.-G., Sheppard, D. C., Park, S., & Perlin, D. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl022 · Cited by 192 · see citing works
Multilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedClades
Dodgson, A. R., Pujol, C., Denning, D. W., Soll, D. R., & Fox, A. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5709-5717.2003 · Cited by 191 · see citing works
Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility
Katiyar, S. K., Pfaller, M. A., & Edlind, T. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189 · see citing works
Acquired resistance to echinocandins in Candida albicans: case report and review
Baixench, M.-T., Aoun, N. B. T., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, É. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 149 · see citing works
Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy
Hakki, M., Staab, J. F., & Marr, K. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00148-06 · Cited by 148 · see citing works
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Kahn, J. N., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K. A., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-07 · Cited by 118 · see citing works
Self-citation
Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin
Miller, C., Lomaestro, B. W., Park, S., & Perlin, D. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.877 · Cited by 93 · see citing works
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85 · see citing works
Emergence of disseminated candidiasis caused byCandida kruseiduring treatment with caspofungin: Case report and review of literature
Pelletier, R., Alarie, I., Lagacé, R., & Walsh, T. J. (2005) · Medical Mycology · doi:10.1080/13693780500220415 · Cited by 59 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

[3]3. Ernst, E. J., J. G. Miller, R. Peson, M. J. Klevay, M. Pfaller, and D. J. Diekema. 2006. Risk factors for C. glabrata bloodstream infection: a case control study, abstr. M897. Abstr. 18th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.

Sorted by citations

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · see citing works
Antifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394 · see citing works
Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377 · see citing works
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
Pfaller, M. A., Diekema, D. J., Andes, D. R., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M. R., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 335 · see citing works
Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- <scp>d</scp> -Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323 · see citing works
Mechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313 · see citing works
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299 · see citing works
Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation
Sanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285 · see citing works
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274 · see citing works
Self-citation
Fungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267 · see citing works
Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans : Implications for Interpretive Breakpoints
Garcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256 · see citing works
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250 · see citing works
Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231 · see citing works
Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01398-10 · Cited by 228 · see citing works
Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: Should the clinical laboratory be testing this agent?
Espinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216 · see citing works
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 204 · see citing works
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196 · see citing works
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C. P., Appanna, V. D., Singh, R. I., Saunders, D., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 196 · see citing works
Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008–2009)
Pfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.06.015 · Cited by 180 · see citing works
Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus
Gonçalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F. G. M., & Colombo, A. L. (2016) · Mycoses · doi:10.1111/myc.12469 · Cited by 182 · see citing works
The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata
Shields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171 · see citing works
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)
Espinel‐Ingroff, A., Cuenca‐Estrella, M., Fothergill, A. W., Fuller, J., Ghannoum, M. A., Johnson, E. M., Peláez, T., Pfaller, M. A., & Turnidge, J. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-11 · Cited by 165 · see citing works
Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection
Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 159 · see citing works
Echinocandin Susceptibility Testing ofCandidaSpecies: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media
Arendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158 · see citing works
Self-citation
Fks1 and Fks2 Are Functionally Redundant but Differentially Regulated in Candida glabrata: Implications for Echinocandin Resistance
Katiyar, S. K., Alastruey-Izquierdo, A., Healey, K. R., Johnson, M. E., Perlin, D. S., & Edlind, T. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00813-12 · Cited by 148 · see citing works
Self-citation
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145 · see citing works
FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136 · see citing works
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
Fera, M. T., Camera, E. L., & Sarro, A. D. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.67 · Cited by 134 · see citing works
Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins
García‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 134 · see citing works
Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies
García‐Effrón, G., Kontoyiannis, D. P., Lewis, R. E., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00802-08 · Cited by 129 · see citing works
Antifungal drug resistance mechanisms
Pemán, J., Cantón, E., & Espinel‐Ingroff, A. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.18 · Cited by 121 · see citing works
Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations
Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117 · see citing works
Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches
Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109 · see citing works
Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient
Chapeland‐Leclerc, F., Hennequin, C., Papon, N., Noël, T., Girard, A., Socié, G., Ribaud, P., & Lacroix, C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01138-09 · Cited by 104 · see citing works
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
García‐Effrón, G., Chua, D. J., Tomada, J. R. T., DiPersio, J. R., Perlin, D. S., Ghannoum, M. A., & Bonilla, H. F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-09 · Cited by 104 · see citing works
Beyond genome sequencing: Lineage tracking with barcodes to study the dynamics of evolution, infection, and cancer
Blundell, J. R., & Levy, S. F. (2014) · Genomics · doi:10.1016/j.ygeno.2014.09.005 · Cited by 99 · see citing works
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99 · see citing works
Recent Trends in the Epidemiology of Fungal Infections
Seagle, E. E., Williams, S., & Chiller, T. M. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.001 · Cited by 96 · see citing works
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Caspofungin and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)
Espinel‐Ingroff, A., Fothergill, A. W., Fuller, J., Johnson, E. M., Peláez, T., & Turnidge, J. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01730-10 · Cited by 95 · see citing works
Changes in Cell Wall Synthesis and Ultrastructure during Paradoxical Growth Effect of Caspofungin on Four Different Candida Species
Bizerra, F. C., Melo, A. S. D. A., Katchburian, E., Freymüller, E. H., Straus, A. H., Takahashi, H. K., & Colombo, A. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-10 · Cited by 92 · see citing works
Antifungal drug resistance: do molecular methods provide a way forward?
Perlin, D. S. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283321ce5 · Cited by 89 · see citing works
Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
Lewis, R. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 89 · see citing works
<scp>CRS–MIS</scp> in <scp>C</scp>andida glabrata: sphingolipids modulate echinocandin–<scp>Fks</scp> interaction
Healey, K. R., Katiyar, S. K., Raj, S., & Edlind, T. D. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08194.x · Cited by 79 · see citing works
Antifungal Susceptibility Testing: A Primer for Clinicians
Wiederhold, N. P. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab444 · Cited by 80 · see citing works
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review
Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 66 · see citing works
Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium solani as Evidenced by Hybrid Expression in Saccharomyces cerevisiae
Katiyar, S. K., & Edlind, T. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00020-09 · Cited by 68 · see citing works
Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes
Song, J., & Stevens, D. A. (2015) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1068271 · Cited by 62 · see citing works
Differential Activities of Three Families of Specific β(1,3)Glucan Synthase Inhibitors in Wild-type and Resistant Strains of Fission Yeast
Martins, I. M., Cortés, J. C. G., Muñoz-García, J., Moreno, M. B., Ramos, M., Clemente‐Ramos, J. Á., Durán, Á., & Ribas, J. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174300 · Cited by 61 · see citing works
Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata
Tscherner, M., Schwarzmüller, T., & Kuchler, K. (2011) · Pharmaceuticals · doi:10.3390/ph4010169 · Cited by 60 · see citing works
Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02120-10 · Cited by 59 · see citing works
Genetic basis of antifungal drug resistance
Marie, C. S., & White, T. C. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0021-y · Cited by 59 · see citing works
Set of Classical PCRs for Detection of Mutations in Candida glabrata FKS Genes Linked with Echinocandin Resistance
Dudiuk, C., Gamarra, S., Leonardeli, F., Jimenez-Ortigosa, C., Vitale, R. G., Afeltra, J., Perlin, D. S., & Garcia-Effron, G. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01038-14 · Cited by 50 · see citing works
Development of a Luminex-Based Multiplex Assay for Detection of Mutations Conferring Resistance to Echinocandins in Candida glabrata
Pham, C. D., Bolden, C. B., Kuykendall, R. J., & Lockhart, S. R. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.03378-13 · Cited by 50 · see citing works
Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity
Niimi, K., Monk, B. C., Hirai, A., Hatakenaka, K., Umeyama, T., Lamping, E., Maki, K., Tanabe, K., Kamimura, T., Ikeda, F., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq073 · Cited by 47 · see citing works
Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.
Jensen, R. H., Johansen, H. K., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-12 · Cited by 47 · see citing works
Old and new pathogenicNakaseomycesspecies: epidemiology, biology, identification, pathogenicity and antifungal resistance
Angoulvant, A., Guitard, J., & Hennequin, C. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov114 · Cited by 45 · see citing works
Clinical and Laboratory Development of Echinocandin Resistance in Candida glabrata: Molecular Characterization
Rivero-Menéndez, O., Navarro-Rodríguez, P., Bernal‐Martínez, L., Martin-Cano, G., Lopez-Perez, L., Sánchez‐Romero, I., Pérez‐Ayala, A., Capilla, J., Zaragoza, Ó., & Alastruey‐Izquierdo, A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01585 · Cited by 45 · see citing works
Evaluation of Caspofungin Susceptibility Testing by the New Vitek 2 AST-YS06 Yeast Card Using a Unique Collection of FKS Wild-Type and Hot Spot Mutant Isolates, Including the Five Most Common Candida Species
Astvad, K. M., Perlin, D. S., Johansen, H. K., Jensen, R. H., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01382-12 · Cited by 43 · see citing works
Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure
Arastehfar, A. A., Daneshnia, F., Salehi, M., Yaşar, M., Hoşbul, T., İlkit, M., Pan, W., Hagen, F., Arslan, N. P., Dağı, H. T., et al. (2020) · Mycoses · doi:10.1111/myc.13104 · Cited by 42 · see citing works
Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations
Lepak, A. J., Castanheira, M., Diekema, D. J., Pfaller, M. A., & Andes, D. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-12 · Cited by 42 · see citing works
Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin
Oliva, A., Rosa, F. G. D., Mikulska, M., Pea, F., Sanguinetti, M., Tascini, C., & Venditti, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2240956 · Cited by 40 · see citing works
Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods
Montagna, M. T., Lovero, G., Coretti, C., Martinelli, D., Giglio, O. D., Iatta, R., Balbino, S., Rosato, A., & Caggiano, G. (2015) · BMC Microbiology · doi:10.1186/s12866-015-0442-4 · Cited by 32 · see citing works
Resistance to antifungal therapies
Prasad, R., Banerjee, A., & Shah, A. H. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160067 · Cited by 33 · see citing works
Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update
Wilson, D. T., Drew, R. H., & Perfect, J. R. (2009) · Mycopathologia · doi:10.1007/s11046-009-9193-9 · Cited by 31 · see citing works
Improved Detection of Candida sp. fks Hot Spot Mutants by Using the Method of the CLSI M27-A3 Document with the Addition of Bovine Serum Albumin
García‐Effrón, G., Park, S., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01350-10 · Cited by 30 · see citing works
Candida glabrata Mutants Demonstrating Paradoxical Reduced Caspofungin Susceptibility but Increased Micafungin Susceptibility
Healey, K. R., Katiyar, S. K., Castanheira, M., Pfaller, M. A., & Edlind, T. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00044-11 · Cited by 30 · see citing works
DifferentialAspergillus lentulusEchinocandin Susceptibilities Are Fksp Independent
Staab, J. F., Kahn, J. N., & Marr, K. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00774-10 · Cited by 30 · see citing works
Recurrent Episodes of Candidemia Due to Candida glabrata with a Mutation in Hot Spot 1 of the FKS2 Gene Developed after Prolonged Therapy with Caspofungin
Durán-Valle, M. T., Gago, S., Gómez‐López, A., Cuenca‐Estrella, M., Diez-Canseco, L. J., Gómez-Garcés, J. L., & Zaragoza, Ó. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06100-11 · Cited by 26 · see citing works
Antifungal resistance does not necessarily affectCandida glabratafitness
Borghi, E., Andreoni, S., Cirasola, D., Ricucci, V., Sciota, R., & Morace, G. (2014) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000100 · Cited by 25 · see citing works
Development of echinocandin‐resistant C andida albicans candidemia following brief prophylactic exposure to micafungin therapy
Ruggero, M. A., & Topal, J. E. (2014) · Transplant Infectious Disease · doi:10.1111/tid.12230 · Cited by 23 · see citing works
Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients
Glöckner, A., & Karthaus, M. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01885.x · Cited by 23 · see citing works
Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates
Bordallo-Cardona, M. Á., Marcos-Zambrano, L. J., Sánchez‐Carrillo, C., de la Pedrosa, E. G. G., Cantón, R., Bouza, E., Escribano, P., & Guinea, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01982-17 · Cited by 21 · see citing works
Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria
Aigner, M., Erbeznik, T., Gschwentner, M., & Lass‐Flörl, C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00512-17 · Cited by 21 · see citing works
Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial Candida glabrata isolates
Misas, E., Seagle, E. E., Jenkins, E. N., Rajeev, M., Hurst, S. F., Nunnally, N. S., Bentz, M. L., Lyman, M., Berkow, E. L., Harrison, L. H., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-23 · Cited by 18 · see citing works
Prevalence and Antifungal Susceptibility of the Emerging Fungal Species, Candida nivariensis , Isolated in a Teaching Hospital in Poland
Sikora, M., Kuthan, R., Piskorska, K., Gołaś-Prądzyńska, M., Domański, D., AUGUSTYNOWICZ-KOPEĆ, E. M., & Swoboda‐Kopeć, E. (2019) · Polish Journal of Microbiology · doi:10.33073/pjm-2019-032 · Cited by 18 · see citing works
Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression
Niimi, K., Woods, M. A., Maki, K., Nakayama, H., Hatakenaka, K., Chibana, H., Ikeda, F., Ueno, K., Niimi, M., Cannon, R. D., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks112 · Cited by 18 · see citing works
A Review on Molecular Mechanisms of Antifungal Resistance in Candida glabrata : Update and Recent Advances
Lotfali, E., Fattahi, A., Sayyahfar, S., Ghasemi, R., Rabiei, M. M., Fathi, M., Vakili, K. G., Deravi, N., Soheili, A., Toreyhi, H., et al. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0235 · Cited by 17 · see citing works
Candida glabrata: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen
Pfaller, M. A., Castanheira, M., Lockhart, S. R., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0091-0 · Cited by 17 · see citing works
Antifungal Resistance Testing and Implications for Management
Badali, H., & Wiederhold, N. P. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00354-6 · Cited by 16 · see citing works
Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species
Fothergill, A. W., McCarthy, D. I., Bataineh, M. T. A., Sanders, C. J., McElmeel, M., & Wiederhold, N. P. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02659-15 · Cited by 14 · see citing works
Inflammatory Cell Recruitment in Candida glabrata Biofilm Cell-Infected Mice Receiving Antifungal Chemotherapy
Rodrigues, C. F., Correia, A., Vilanova, M., & Henriques, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020142 · Cited by 15 · see citing works
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
Wiederhold, N. P., Cota, & Frei, C. R. (2009) · Infection and Drug Resistance · doi:10.2147/idr.s3864 · Cited by 12 · see citing works
Comparison of fks gene mutations and minimum inhibitory concentrations for the detection of Candida glabrata resistance to micafungin: A systematic review and meta‐analysis
Bienvenu, A., Leboucher, G., & Picot, S. (2019) · Mycoses · doi:10.1111/myc.12929 · Cited by 12 · see citing works
Caspofungin resistance in clinical Aspergillus flavus isolates
Yassin, Z., Lotfali, E., Khourgami, M. R., Omidi, N., Fattahi, A., Nasrollahi, S. A., & Ghasemi, R. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101166 · Cited by 10 · see citing works
In vitro activity of echinocandins against non-Candida albicans: Is echinocandin antifungal activity the same?
Espinel‐Ingroff, A., & Cantón, E. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70002-7 · Cited by 11 · see citing works
In Vitro Antifungal Susceptibility of Candida glabrata to Caspofungin and the Presence of FKS Mutations Correlate with Treatment Response in an Immunocompromised Murine Model of Invasive Infection
Fernández‐Silva, F., Lackner, M., Capilla, J., Mayayo, E., Sutton, D. A., Castanheira, M., Fothergill, A. W., Lass‐Flörl, C., & Guarro, J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02666-13 · Cited by 10 · see citing works
Influence of Serum and Albumin on Echinocandin In Vitro Potency and Pharmacodynamics
Nasar, A., Ryan, L., Frei, C. R., Cota, J. M., & Wiederhold, N. P. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0136-z · Cited by 9 · see citing works
A novel calcineurin-independent activity of cyclosporin A in Saccharomyces cerevisiae
Singh-Babak, S. D., Shekhar, T., Smith, A. M., Giaever, G. N., Nislow, C., & Cowen, L. E. (2012) · Molecular BioSystems · doi:10.1039/c2mb25107h · Cited by 9 · see citing works
Diagnosis of Antifungal Drug Resistance Mechanisms in Fungal Pathogens: Transcriptional Gene Regulation
Sanglard, D. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0055-9 · Cited by 6 · see citing works
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_18 · Cited by 6 · see citing works
The Mechanisms of Resistance to Echinocandin Class of Antifungal Drugs
Niimi, K., & Niimi, M. (2009) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.50.057 · Cited by 6 · see citing works
Antifungal Resistance: Cellular and Molecular Mechanisms
Araújo, R., & Espinel‐Ingroff, A. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_7 · Cited by 5 · see citing works
Emerging Resistance to Azoles and Echinocandins: Clinical Relevance and Laboratory Detection
Espinel‐Ingroff, A., Pfaller, M. A., Cantón, E., & Pemán, J. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0026-6 · Cited by 5 · see citing works
Multidrug- and Cross-Resistant Candida: the Looming Threat
Lackner, M., Martín‐Vicente, A., & Lass‐Flörl, C. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0210-1 · Cited by 4 · see citing works
Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins
Pfaller, M. A., Diekema, D. J., Castanheira, M., & Jones, R. N. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0053-y · Cited by 4 · see citing works
Echinocandins
Groll, A. H., Schrey, D., & Walsh, T. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_6 · Cited by 4 · see citing works
Resistance to Antifungal Drugs
Sanglard, D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_9 · Cited by 3 · see citing works
Susceptibility to caspofungin is regulated by temperature and is dependent on calcineurin in Candida albicans
Zheng, L., Xu, Y., Wang, C., Yang, F. J., Dong, Y., & Guo, L. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01790-23 · Cited by 3 · see citing works
Evolution and Genomics of the PathogenicCandidaSpecies Complex
Butler, G., Lorenz, M., & Gow, N. A. R. (2012) · Wiley eBooks · doi:10.1002/9781118308165.ch21 · Cited by 3 · see citing works
Whole genome sequencing analysis of Candida glabrata isolates collected from patients with selected drug-resistant candidiasis hospitalized in Eastern Poland
Kubica, S., Szulińska, W., Kruszniewska‐Rajs, C., Kimsa‐Dudek, M., Olender, A., Bogut, A., Szukała, M., Dąbrowski, W., Pietrzak, D., Gagoś, M., et al. (2025) · Folia Microbiologica · doi:10.1007/s12223-025-01298-w · Cited by 2 · see citing works

Recurrent Episodes of Candidemia Due to Candida glabrata with a Mutation in Hot Spot 1 of the FKS2 Gene Developed after Prolonged Therapy with Caspofungin
Durán-Valle, M. T., Gago, S., Gómez‐López, A., Cuenca‐Estrella, M., Diez-Canseco, L. J., Gómez-Garcés, J. L., & Zaragoza, Ó. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06100-11 · Cited by 26 · see citing works
Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection
Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 159 · see citing works
[Case of candidemia with Candida glabrata with confirmation of the acquisition of micafungin sensitivity due to new mutation of FKS gene mutation].
Saraya, T., Watanabe, T., Tsujimoto, N., Takata, S., Araki, K., Makino, H., Yonetani, S., Takizawa, H., & Goto, H. (2014) · PubMed · Cited by 1 · see citing works
Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231 · see citing works
FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136 · see citing works

Authors: Cleary, J. D., Garcia-Effron, G., Chapman, S. W., & Perlin, D. S.
Affiliations: University of Mississippi (US)
Public Health Research Institute, UMDNJ-New Jersey Medical School, Newark, New Jersey
Rutgers New Jersey Medical School (US)
Corresponding author: Cleary, John D.
ORCID: Cleary, John D.
Perlin, David S.
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2008-06
Volume: 52
Issue: 6
Pages: 2263-2265
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.01568-07
PMC: PMC2415792
OpenAlex: W2167509781
Cited by: 118
References: 15
Citations by year: 2026: 2 · 2025: 1 · 2024: 1 · 2023: 3 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 9 · 2013: 5 · 2012: 16
FWCI: 11.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords: Candida glabrata, candidemia, caspofungin, FKS1 mutations, fluconazole resistance, clonal isolates, recurrent fungal infection, antifungal susceptibility, echinocandin resistance
MeSH terms: Caspofungin, Aged, Antifungal Agents, Candidiasis, Female, Fungal Proteins, Glucosyltransferases, Humans, Membrane Proteins, Microbial Sensitivity Tests, Mutation, Fungemia, Fatal Outcome, Drug Resistance, Fungal, Candida glabrata, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks